Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules

Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules

The phosphodiesterase (PDE) enzymes, key regulator of the cyclic nucleotide signal transduction system, are long-established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a particularly high number of clinical trials involving PDE inhibi...

Full description

Bibliographic Details
Main Authors:	Andrey D. Bondarev, Misty M. Attwood, Jörgen Jonsson, Vladimir N. Chubarev, Vadim V. Tarasov, Wen Liu, Helgi B. Schiöth
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Pharmacology
Subjects:	PDE inhibition cyclic nucleotides second messengers sildenafil roflumilast apremilast
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1057083/full

Similar Items

Phosphodiesterase-4 Inhibition in the Management of Psoriasis
by: Erika L. Crowley, et al.
Published: (2023-12-01)

Differential effects of two phosphodiesterase 4 inhibitors against lipopolysaccharide-induced neuroinflammation in mice
by: Dong Ho Kang, et al.
Published: (2023-07-01)

[Translated aticle] Topical and Oral Roflumilast in Dermatology: A Narrative Review
by: M. Mansilla-Polo, et al.
Published: (2024-03-01)

Roflumilast tópico y oral en dermatología. Una revisión narrativa
by: M. Mansilla-Polo, et al.
Published: (2024-03-01)

Role of Cyclic Nucleotide Phosphodiesterases in Inner Ear and Hearing
by: Rahul Mittal, et al.
Published: (2017-11-01)

Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials
by: Qin Kang, et al.
Published: (2022-10-01)

Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012
by: Susann Schröder, et al.
Published: (2016-05-01)

Apicomplexan phosphodiesterases in cyclic nucleotide turnover: conservation, function, and therapeutic potential
by: William J. Moss, et al.
Published: (2024-02-01)

Challenges on Cyclic Nucleotide Phosphodiesterases Imaging with Positron Emission Tomography: Novel Radioligands and (Pre-)Clinical Insights since 2016
by: Susann Schröder, et al.
Published: (2021-04-01)

Phosphodiesterase Inhibitors: Present and Future
by: José L. Izquierdo-Alonso
Published: (2023-01-01)

Pulmonary vasodilation by sildenafil in acute intermediate-high risk pulmonary embolism: a randomized explorative trial
by: Asger Andersen, et al.
Published: (2021-02-01)

Inhibition of PDE‐4 isoenzyme attenuates frequency and overall contractility of agonist‐evoked ureteral phasic contractions
by: Iris Lim, et al.
Published: (2024-02-01)

The Complexity and Multiplicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches
by: Claire Lugnier
Published: (2022-09-01)

Repurposing Phosphodiesterase-5 inhibitors as chemoadjuvants
by: Amit K. Tiwari, et al.
Published: (2013-06-01)

Future options for disease intervention: important advances in phosphodiesterase 4 inhibitors
by: R. A. McIvor
Published: (2007-09-01)

Roflumilast: Review of Phosphodiesterase-4 Inhibitor as Asthma Therapy
by: Rafina Syfridiana, et al.
Published: (2021-08-01)

Phosphodiesterase 4 Inhibitor Roflumilast Protects Rat Hippocampal Neurons from Sevoflurane Induced Injury via Modulation of MEK/ERK Signaling Pathway
by: Sheng Peng, et al.
Published: (2018-03-01)

Putative Nucleotide-Based Second Messengers in the Archaeal Model Organisms Haloferax volcanii and Sulfolobus acidocaldarius
by: Frank Braun, et al.
Published: (2021-11-01)

Progress in Understanding the Molecular Basis Underlying Functional Diversification of Cyclic Dinucleotide Turnover Proteins
by: Römling, Ute, et al.
Published: (2017)

Management of scrotal pruritus with topical roflumilast 0.3% once daily treatment
by: Paul S. Yamauchi, MD, PhD
Published: (2024-05-01)

Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases
by: Theerasuk Kawamatawong
Published: (2021-08-01)

Apremilast ameliorates acute respiratory distress syndrome by inhibiting neutrophil-induced oxidative stress
by: Yung-Fong Tsai, et al.
Published: (2023-08-01)

Development of Single-Molecule Electrical Identification Method for Cyclic Adenosine Monophosphate Signaling Pathway
by: Yuki Komoto, et al.
Published: (2021-03-01)

Cyclic nucleotide phosphodiesterases in health and disease /
by: Beavo, Joe, et al.
Published: (2007)

Phosphodiesterase 4B: Master Regulator of Brain Signaling
by: Amy J. Tibbo, et al.
Published: (2020-05-01)

Longstanding tracheobronchomalacia: A forgotten cause of severe cough and its response to roflumilast
by: Veronica Ann Varney, et al.
Published: (2020-01-01)

Crushed apremilast for the treatment of oral lichen planus
by: Penelope Kim-Lim, BS, et al.
Published: (2023-07-01)

Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation
by: Barbara Meier-Schiesser, et al.
Published: (2021-11-01)

Phosphodiesterase-4 Inhibitor Roflumilast-Mediated Protective Effect in Sepsis-Induced Late-Phase Event of Acute Kidney Injury: A Narrative Review
by: Imran Kazmi, et al.
Published: (2022-07-01)

Retinal toxicity of long term overdose of sildenafil citrate: A case report
by: Huichao Yan, et al.
Published: (2023-03-01)

In Silico, Ex Vivo and In Vivo Studies of Roflumilast as a Potential Antidiarrheal and Antispasmodic agent: Inhibition of the PDE-4 Enzyme and Voltage-gated Ca++ ion Channels
by: Najeeb Ur Rehman, et al.
Published: (2020-02-01)

Genetic Association of Phosphodiesterases With Human Cognitive Performance
by: Mark E. Gurney
Published: (2019-02-01)

Case report: Treatment of psoriasiform dermatitis in patients with malignancy
by: Jinzhu Mao, et al.
Published: (2024-04-01)

Crystal structure of an apremilast ethanol hemisolvate hemihydrate solvatomorph
by: Yun-Deng Wu, et al.
Published: (2017-06-01)

Physiological Sensing of Carbon Dioxide/Bicarbonate/pH via Cyclic Nucleotide Signaling
by: Lonny R. Levin, et al.
Published: (2011-02-01)

Phosphodiesterases Expression during Murine Cardiac Development
by: Thays Maria da Conceição Silva Carvalho, et al.
Published: (2021-03-01)

Pharmacokinetics of single- and multiple-dose roflumilast: an open-label, three-way crossover study in healthy Chinese volunteers
by: Huang J, et al.
Published: (2018-11-01)

Radiosynthesis and Biological Investigation of a Novel Fluorine-18 Labeled Benzoimidazotriazine-Based Radioligand for the Imaging of Phosphodiesterase 2A with Positron Emission Tomography
by: Rien Ritawidya, et al.
Published: (2019-11-01)

Effect of Roflumilast in airways disorders via dual inhibition of phosphodiesterase and Ca2+-channel
by: Faisal Imam, et al.
Published: (2020-06-01)

Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts
by: Tannheimer Stacey L, et al.
Published: (2012-03-01)